Atherosclerosis Treatment Drugs Market- Restraints
However, the side effects associated with atherosclerosis drugs and limited efficacy of the drugs
is expected to hamper atherosclerosis market growth. For instance, in November 2016, The
Lancet led by Rory Collins, provided an evidence on statin therapy and the methodological
limitations. As per data, statins are associated with increased incidence of diabetes and
hemorrhagic stroke. Statins tends to increase the risk of type 2 diabetes in a dose-dependent
mode.
Atherosclerosis Treatment Drugs Market- Regional Analysis
On the basis of region, the global atherosclerosis treatment drugs market is segmented into
North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Geographically, North America is expected to gain significant market share over the forecast
period, owing to increasing incidences of atherosclerotic condition among the population in this
region. For instance, in November 2016, as per data provided by the U.S. Centers for Disease
Control and Prevention (CDC) and the World Health Organization (WHO), there were more than
15.5 million Americans who had coronary artery disease and it is expected that for every 42
seconds an American will experience the onset of a myocardial infarction.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/2430
Furthermore, Asia Pacific is expected to witness significant growth in the market, owing to
expansion of major key players in this region. For instance, in October 2017, GSK opened its
new regional headquarters for Asia in Singapore. The GSK’s purpose for building headquarters
is to support the pharmaceutical, vaccines, and consumer healthcare businesses across multiple
regions in Asia Pacific.